Home › Research › TREM2 and immune genetics
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness
Indira Chandran V, Wernberg CW, Lauridsen MM, Skytthe MK, Bendixen SM, Larsen FT, Hansen CD, Grønkjær LL et al.. Hepatology (Baltimore, Md.), 2022-07-14
Topic: Brain proteins, microglia and lab models
Background and aims Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness. Approach and results We collected cross-sectional, clinical data including liver biopsies from a derivation ( n = 48) and a validation cohort ( n = 170) of patients with elevated liver stiffness measurement (LSM ≥ 8.0 kPa).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Indira Chandran, V., Wernberg, C. W., Lauridsen, M. M., Skytthe, M. K., Bendixen, S. M., Larsen, F. T., et al. (2023). Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness. Hepatology (Baltimore, Md.). https://doi.org/10.1002/hep.32620
Vancouver
Indira Chandran V, Wernberg CW, Lauridsen MM, Skytthe MK, Bendixen SM, Larsen FT, et al. Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness. Hepatology (Baltimore, Md.). 2023. doi:10.1002/hep.32620. PMID: 35712786.
BibTeX
@article{indirachandran2023-35712786,
author = {Indira Chandran, V. and Wernberg, C. W. and Lauridsen, M. M. and Skytthe, M. K. and Bendixen, S. M. and Larsen, F. T. and Hansen, C. D. and Grønkjær, L. L. and others},
title = {{Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness}},
journal = {Hepatology (Baltimore, Md.)},
year = {2023},
doi = {10.1002/hep.32620},
pmid = {35712786},
url = {https://doi.org/10.1002/hep.32620}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness.
- Approach and results We collected cross-sectional, clinical data including liver biopsies from a derivation ( n = 48) and a validation cohort ( n = 170) of patients with elevated liver stiffness measurement (LSM ≥ 8.0 kPa).
- Patients with NAFLD activity scores (NAS) ≥4 were defined as having NASH.
- Plasma TREM2 levels were significantly elevated in patients with NASH of the derivation cohort, with an area under the receiver operating characteristics curve (AUROC) of 0.92 (95% confidence interval [CI], 0.84-0.99).
Why it matters
This study examined plasma TREM2 as a diagnostic biomarker for NASH in patients with elevated liver stiffness. It is about liver disease, not Alzheimer's disease, and does not show a treatment or cure for Alzheimer's.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcross-sectional
- Participants48
- Evidence strengthModerate
How this study scored 56/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Hepatology (Baltimore, Md.)) |
| Journal's citation record | 3 / 4 | Hepatology: journal h-index 480 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 48 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 62 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 12.4 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 3 / 6 | Cited 7.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 43 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Jonas Heilskov Graversen: h-index 30 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Aarhus University: institution h-index 976 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35712786) |
| Free to read | 2 / 2 | Free to read |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in TREM2 and immune genetics
Also tagged “macrophages”
363 studies in the library carry the topic tag “macrophages”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.